A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia

Journal of Psychiatric Research

Volumn 73, Issue , 2016, Pages 34-44

  Pawełczyk, Tomasz ^a   Grancow Grabka, Marta ^b   Kotlicka Antczak, Magdalena ^a   Trafalska, Elzbieta ^a   Pawełczyk, Agnieszka ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Centralny Szpital Kliniczny UM w odzi   (Poland)

Author keywords

Docosahexaenoic acid; Eicosapentaenoic acid; Fatty acids; Omega 3; Randomized controlled trial; Schizophrenia first episode

Indexed keywords

OLIVE OIL; OMEGA 3 FATTY ACID; PLACEBO; ETHYL EICOSAPENTAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL GLOBAL IMPRESSION SCALE; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; EFFECT SIZE; ENERGY CONSUMPTION; FEMALE; FUNCTIONAL ASSESSMENT; GLOBAL ASSESSMENT OF FUNCTIONING; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SHELTERED WORKSHOP; AGE; ANALOGS AND DERIVATIVES; DIETARY SUPPLEMENT; FOLLOW UP; MENTAL HEALTH; REPRODUCIBILITY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; ANTIPSYCHOTIC AGENTS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FEMALE; FISH OILS; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL STATUS SCHEDULE; OUTCOME ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84959011001     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2015.11.013     Document Type: Article

References (67)

1. Abedi E., Sahari M.A. Long-chain polyunsaturated fatty acid sources and evaluation of their nutritional and functional properties. Food Sci. Nutr. 2014, 2(5):443-463.
2. Addington D., Addington J., Maticka-Tyndale E., Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr. Res. 1992, 6(3):201-208.
3. Amminger G.P., Schafer M.R., Papageorgiou K., Klier C.M., Cotton S.M., Harrigan S.M., Mackinnon A., McGorry P.D., Berger G.E. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch. General Psychiatry 2010, 67(2):146-154.
4. Andrade C. The numbers needed to treat and harm (NNT, NNH) statistics: what they tell us and what they do not. J. Clin. Psychiatry 2015, 76(3):e330-e333.
5. Andreasen N.C., Pressler M., Nopoulos P., Miller D., Ho B. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol. Psychiatry 2010, 67(3):255-262.
6. Bach S.A., de Siqueira Leticia V., Muller A.P., Oses J.P., Quatrim A., Emanuelli T., Vinade L., Souza D.O., Moreira J.D. Dietary omega-3 deficiency reduces BDNF content and activation NMDA receptor and Fyn in dorsal hippocampus: implications on persistence of long-term memory in rats. Nutr. Neurosci. 2014, 17(4):186-192.
7. Bentsen H., Osnes K., Refsum H., Solberg D.K., Bohmer T. A randomized placebo-controlled trial of an omega-3 fatty acid and vitamins E+C in schizophrenia. Transl. Psychiatry 2013, 3:e335.
8. Berger G.E., Proffitt T., McConchie M., Yuen H., Wood S.J., Amminger G.P., Brewer W., McGorry P.D. Ethyl-eicosapentaenoic acid in first-episode psychosis: a randomized, placebo-controlled trial. J. Clin. Psychiatry 2007, 68(12):1867-1875.
9. Berger G.E., Wood S.J., Pantelis C., Velakoulis D., Wellard R.M., McGorry P.D. Implications of lipid biology for the pathogenesis of schizophrenia. Aust. N. Z. J. Psychiatry 2002, 36(3):355-366.
10. Berger G.E., Wood S.J., Wellard R.M., Proffitt T.M., McConchie M., Amminger G.P., Jackson G.D., Velakoulis D., Pantelis C., McGorry P.D. Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study. Biol. Psychiatry 2008, 33(10):2467-2473.
11. Bradbury J. Docosahexaenoic acid (DHA): an ancient nutrient for the modern human brain. Nutrients 2011, 3(5):529-554.
12. Brown I., Cascio M.G., Rotondo D., Pertwee R.G., Heys S.D., Wahle Klaus W.J. Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators. Prog. Lipid Res. 2013, 52(1):80-109.
13. Calder P.C. Mechanisms of action of (n-3) fatty acids. J. Nutr. 2012, 142(3):592S-599S.
14. Calder P.C. n-3 fatty acids, inflammation and immunity: new mechanisms to explain old actions. Proc. Nutr. Soc. 2013, 72(3):326-336.
15. Carbon M., Correll C.U. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialog. Clin. Neurosci. 2014, 16(4):505-524.
16. Carver J.D., Benford V.J., Han B., Cantor A.B. The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects. Brain Res. Bull. 2001, 56(2):79-85.
17. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, L. Erlbaum Associates, Hillsdale N.J.
18. Dehghan M., Ilow R., Zatonska K., Szuba A., Zhang X., Mente A., Regulska-Ilow B. Development, reproducibility and validity of the food frequency questionnaire in the Poland arm of the Prospective Urban and Rural Epidemiological (PURE) study. J. Hum. Nutr. Diet. Off. J. Br. Diet. Assoc. 2012, 25(3):225-232.
19. Emsley R., Myburgh C., Oosthuizen P., van Rensburg Susan J. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am. J. Psychiatry 2002, 159(9):1596-1598.
20. Emsley R., Niehaus Dana J.H., Koen L., Oosthuizen P.P., Turner H.J., Carey P., van Rensburg Susan Janse, Maritz J.S., Murck H. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr. Res. 2006, 84(1):112-120.
21. Fenton W.S., Dickerson F., Boronow J., Hibbeln J.R., Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am. J. Psychiatry 2001, 158(12):2071-2074.
22. Friedman L.M., Furberg C., DeMets D.L. Fundamentals of Clinical Trials 2010, Springer, New York.
23. Fusar-Poli P., Berger G. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. J. Clin. Psychopharmacol. 2012, 32(2):179-185.
24. Gama C.S., Canever L., Panizzutti B., Gubert C., Stertz L., Massuda R., Pedrini M., de Lucena David F., Luca R.D., Fraga D.B., Heylmann A.S., Deroza P.F., Zugno A.I. Effects of omega-3 dietary supplement in prevention of positive, negative and cognitive symptoms: a study in adolescent rats with ketamine-induced model of schizophrenia. Schizophr. Res. 2012, 141(2-3):162-167.
25. Gardner D.M., Murphy A.L., O'Donnell H., Centorrino F., Baldessarini R.J. International consensus study of antipsychotic dosing. Am. J. Psychiatry 2010, 167(6):686-693.
26. Grosso G., Pajak A., Marventano S., Castellano S., Galvano F., Bucolo C., Drago F., Caraci F. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PloS one 2014, 9(5):e96905.
27. Guy W. The clinical global impression scale. ECDEU Assessment Manual for Psychopharmacology-revised 1976, 218-222.
28. Hammamieh R., Chakraborty N., Gautam A., Miller S., Muhie S., Meyerhoff J., Jett M. Transcriptomic analysis of the effects of a fish oil enriched diet on murine brains. PloS one 2014, 9(3):e90425.
29. Hoen W.P., Lijmer J.G., Duran M., Wanders Ronald J.A., van Beveren Nico J.M., de Haan L. Red blood cell polyunsaturated fatty acids measured in red blood cells and schizophrenia: a meta-analysis. Psychiatry Res. 2013, 207(1-2):1-12.
30. Hogyes E., Nyakas C., Kiliaan A., Farkas T., Penke B., Luiten P.G.M. Neuroprotective effect of developmental docosahexaenoic acid supplement against excitotoxic brain damage in infant rats. Neuroscience 2003, 119(4):999-1012.
31. Horrobin D.F. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophr. Res. 1998, 30(3):193-208.
32. Jamilian H., Solhi H., Jamilian M. Randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia. Glob. J. Health Sci. 2014, 6(7 Spec No):103-108.
33. Jarema M. Standardy leczenia farmakologicznego niektórych zaburzeń psychicznych 2011, Gdańsk: Via Medica.
34. Jin H., Zisook S., Palmer B.W., Patterson T.L., Heaton R.K., Jeste D.V. Association of depressive symptoms with worse functioning in schizophrenia: a study in older outpatients. J. Clin. Psychiatry 2001, 62(10):797-803.
35. Jones S.H., Thornicroft G., Coffey M., Dunn G. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br. J. Psychiatry J. Ment. Sci. 1995, 166(5):654-659.
36. Joy C.B., Mumby-Croft R., Joy L.A. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst. Rev. 2006, (3):CD001257.
37. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
38. Keleshian V.L., Kellom M., Kim H., Taha A.Y., Cheon Y., Igarashi M., Rapoport S.I., Rao J.S. Neuropathological responses to chronic NMDA in rats are worsened by dietary n-3 PUFA deprivation but are not ameliorated by fish oil supplementation. PloS one 2014, 9(5):e95318.
39. Kotlicka-Antczak M., Pawelczyk T., Rabe-Jablonska J., Pawelczyk A. PORT (Programme of Recognition and Therapy): the first Polish recognition and treatment programme for patients with an at-risk mental state. Early Interv. Psychiatry 2015 Aug, 9(4):339-342.
40. Kraemer H.C. A source of false findings in published research studies: adjusting for covariates. JAMA Psychiatry 2015 Oct 1, 72(10):961-962.
41. Leucht S. Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application. J. Clin. Psychiatry 2014, 75(Suppl. 1):8-14.
42. Leucht S., Arbter D., Engel R.R., Kissling W., Davis J.M. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol. Psychiatry 2009, 14(4):429-447.
43. Leucht S., Davis J.M., Engel R.R., Kane J.M., Wagenpfeil S. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 2007, 32(9):1903-1910.
44. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. 1987, 334(Suppl. l):1-100.
45. Liu H., Zhang H., Xiao W., Liu Q., Fu P., Chen J., Wang G., Yang F., Wang G., Wang X., Li L. Scales for evaluating depressive symptoms in Chinese patients with schizophrenia. J. Nerv. Ment. Dis. 2009, 197(2):140-142.
46. Luchtman D.W., Song C. Cognitive enhancement by omega-3 fatty acids from child-hood to old age: findings from animal and clinical studies. Neuropharmacology 2013, 64:550-565.
47. McEvoy J., Baillie R.A., Zhu H., Buckley P., Keshavan M.S., Nasrallah H.A., Dougherty G.G., Yao J.K., Kaddurah-Daouk R. Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics. PloS one 2013, 8(7):e68717.
48. McNamara R.K. Deciphering the role of docosahexaenoic acid in brain maturation and pathology with magnetic resonance imaging. Prostagl. Leukot. Essent. Fat. Acids 2013, 88(1):33-42.
49. McNamara R.K., Carlson S.E. Role of omega-3 fatty acids in brain development and function: potential implications for the pathogenesis and prevention of psychopathology. Prostagl. Leukot. Essent. Fat. Acids 2006, 75(4-5):329-349.
50. McNamara R.K., Vannest J.J., Valentine C.J. Role of perinatal long-chain omega-3 fatty acids in cortical circuit maturation: mechanisms and implications for psychopathology. World J. Psychiatry 2015, 5(1):15-34.
51. Nestel P., Clifton P., Colquhoun D., Noakes M., Mori T.A., Sullivan D., Thomas B. Indications for omega-3 long chain polyunsaturated fatty acid in the prevention and treatment of cardiovascular disease. Heart Lung Circ. 2015 Aug, 24(8):769-779.
52. Patel M.X., Arista I.A., Taylor M., Barnes Thomas R.E. How to compare doses of different antipsychotics: a systematic review of methods. Schizophr. Res. 2013, 149(1-3):141-148.
53. Patten A.R., Sickmann H.M., Dyer R.A., Innis S.M., Christie B.R. Omega-3 fatty acids can reverse the long-term deficits in hippocampal synaptic plasticity caused by prenatal ethanol exposure. Neurosci. Lett. 2013, 551:7-11.
54. Pawelczyk T., Grancow M., Kotlicka-Antczak M., Trafalska E., Gebski P., Szemraj J., Zurner N., Pawelczyk A. Omega-3 fatty acids in first-episode schizophrenia - a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods. BMC Psychiatry 2015, 15(1):97.
55. Peet M., Brind J., Ramchand C.N., Shah S., Vankar G.K. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr. Res. 2001, 49(3):243-251.
56. Peet M., Horrobin D.F. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J. Psychiatr. Res. 2002, 36(1):7-18.
57. Perkins D.O., Gu H., Boteva K., Lieberman J.A. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am. J. Psychiatry 2005, 162(10):1785-1804.
58. Pottala J.V., Yaffe K., Robinson J.G., Espeland M.A., Wallace R., Harris W.S. Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes: WHIMS-MRI study. Neurology 2014, 82(5):435-442.
59. Rapoport S.I., Rao J.S., Igarashi M. Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver. Prostagl. Leukot. Essent. Fat. Acids 2007, 77(5-6):251-261.
60. Reddy R.D., Keshavan M.S., Yao J.K. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr. Bull. 2004, 30(4):901-911.
61. Rix T.A., Joensen A.M., Riahi S., Lundbye-Christensen S., Tjonneland A., Schmidt E.B., Overvad K.A. U-shaped association between consumption of marine n-3 fatty acids and development of atrial fibrillation/atrial flutter-a Danish cohort study. Eur. Eur. Pacing Arrhythm. Cardiac Electrophysiol. J. Work. Groups Cardiac Pacing Arrhythm. Cardiac Cell. Electrophysiol. Eur. Soc. Cardiol. 2014, 16(11):1554-1561.
62. Sable P.S., Kale A.A., Joshi S.R. Prenatal omega 3 fatty acid supplementation to a micronutrient imbalanced diet protects brain neurotrophins in both the cortex and hippocampus in the adult rat offspring. Metab. Clin. Exp. 2013, 62(11):1607-1622.
63. Savinova O.V., Fillaus K., Harris W.S., Shearer G.C. Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol. Atherosclerosis 2015, 240(2):520-525.
64. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):34-57. 22-33;quiz.
65. Takkunen M.J., Schwab U.S., de Mello Vanessa D.F., Eriksson J.G., Lindstrom J., Tuomilehto J., Uusitupa M.I.J. Longitudinal associations of serum fatty acid composition with type 2 diabetes risk and markers of insulin secretion and sensitivity in the Finnish Diabetes Prevention Study. Eur. J. Nutr. 2015, 10.1007/s00394-015-0911-4.
66. Tollefson G.D., Andersen S.W., Tran P.V. The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. Biol. Psychiatry 1999, 46(3):365-373.
67. Villegas R., Takata Y., Murff H., Blot W.J. Fish, omega-3 long-chain fatty acids, and all-cause mortality in a low-income US population: results from the Southern Community Cohort Study. Nutr. Metab. Cardiovasc. Dis. NMCD 2015, 25(7):651-658.